Stay updated on Vertex Pharmaceuticals Press Releases

Sign up to get notified when there's something new on the Vertex Pharmaceuticals Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Vertex Pharmaceuticals Press Releases page

  1. Check
    7 days ago
    Change Detected
    Summary
    Vertex has received FDA approval for ALYFTREK, a new CFTR modulator, and expanded indications for TRIKAFTA, while recent presentations on exagamglogene autotemcel and TRIKAFTA's long-term benefits have been removed from the site.
    Difference
    11%
    Check dated 2024-12-26T18:10:11.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Vertex has announced results from a Phase 2 study of Suzetrigine for treating painful lumbosacral radiculopathy, while the previous announcement regarding their third quarter 2023 financial results has been removed.
    Difference
    4%
    Check dated 2024-12-19T14:42:50.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Vertex has presented positive long-term data on CASGEVY at the ASH Annual Meeting, while the recent appointment of Michel Lagarde to its Board of Directors has been removed from the site.
    Difference
    4%
    Check dated 2024-12-12T10:36:55.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    Vertex has released its third quarter 2024 financial results, while a previous update on VX-880 results from October 2023 has been removed.
    Difference
    4%
    Check dated 2024-11-20T16:34:58.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Vertex has announced its participation in upcoming November investor conferences and provided updates on its kidney programs at the ASN Annual Kidney Week, while recent deletions include a positive opinion for KAFTRIO and a Breakthrough Prize award.
    Difference
    7%
    Check dated 2024-11-01T11:40:41.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Vertex has announced it will present Phase 3 data on Suzetrigine as a potential first-in-class pain signal inhibitor at the upcoming American Society of Anesthesiologists Annual Meeting on October 18, 2024, while a previous announcement regarding participation in the Morgan Stanley Healthcare Conference has been removed.
    Difference
    5%
    Check dated 2024-10-25T01:24:59.000Z thumbnail image

Stay in the know with updates to Vertex Pharmaceuticals Press Releases

Enter your email address, and we'll notify you when there's something new on the Vertex Pharmaceuticals Press Releases page.